Join
Live feed
·
PRReleasevia Quantisnow
Sagimet Biosciences Inc. logo

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

ByQuantisnow·Wall Street's wire, on your screen.
SGMT· Sagimet Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SGMT (Sagimet Biosciences Inc.) and more on Quantisnow.